Voyageur Pharmaceuticals Ltd. (V:VM*CA)

Business Focus: Pharmaceuticals (NEC)

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: Dome Tower 800, 333 7 Ave. S.W.
CALGARY AB T2P 2Z1
Tel: N/A
Website: https://voyageurpharmaceuticals.ca
IR: See website
<
Key People
Brent Willis
President, Chief Executive Officer, Director
Albert Deslauriers
Chief Financial Officer
Bradly Willis
Chief Operating Officer, Director
Business Overview
Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada and the state of Utah, United States. Its properties include Jubilee Mountain, Falcon and Paradox Basin. It owns a 100% interest in two barium sulphate (barite) projects, including the Frances Creek and Pedley Mountain property. It holds interests in a high-grade iodine, lithium, and bromine brine project situated in Utah, United States. It owns a 100% interest in two battery mineral projects that is focused on copper/zinc development. Its pipeline products include SmoothX 2.0%, MultiX Thick, MultiX Thin, HDX, LDX, VY-101 and VY-103.
Financial Overview
For the fiscal year ended 30 November 2023, Voyageur Pharmaceuticals Ltd revenues was not reported. Net loss decreased 20% to C$1.4M. Lower net loss reflects Market and product development decrease of 47% to C$281K (expense), General and administrative decrease of 42% to C$149K (expense), Wages and benefits decrease of 20% to C$330K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.02 to -C$0.01.
Reporting Currency: Canadian Dollars
Enterprise value: $7.70M as of Nov 30, 2023
Annual revenue (TTM): $0.00M as of Nov 30, 2023
EBITDA (TTM): -$1.34M as of Nov 30, 2023
Net annual income (TTM): -$1.40M as of Nov 30, 2023
Free cash flow (TTM): -$1.17M as of Nov 30, 2023
Net Debt Last Fiscal Year: $0.04M as of Nov 30, 2023
Shares outstanding: 138,881,576 as of Mar 13, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.